STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being seen — and marketed — as a way to look and feel better
Good morning and welcome to the latest edition of our working week coverage. As we return to our usual routine of meetings and deadlines, we're finding our usual cup of tea to be the perfect pick-me-up. Today, we're featuring a honeybush vanilla turmeric blend. In today's news roundup, several topics are gaining attention.
GLP-1 drugs, initially developed to treat obesity, are now being marketed as lifestyle drugs to improve overall health and well-being. This shift in perspective has been embraced by Novo Nordisk, a pioneer in the field, as they capitalize on this trend. However, this change has presented challenges for pharmaceutical giants Merck and Daiichi Sankyo.
Despite their multibillion-dollar cancer alliance, Merck and Daiichi recently withdrew their U.S. application for an experimental lung cancer therapy. The decision was prompted by discussions with the U.S. Food and Drug Administration, who deemed the mid-stage clinical study data insufficient to support accelerated approval. This marks the second pullback for the companies in their cancer alliance, with their previous lung cancer candidate failing to extend patient survival in a late-stage study last year.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
